With the Reblozyl flop, all four of the pivotal trials that have read out this year for BMS’ currently marketed drugs have turned up negative. More: Bristol Myers braves failed Reblozyl ph. 3, plans FDA talks for potential anemia expansion
read moreThe company attributed its decision to cancel its plans for an mRNA manufacturing plant in the country to “changes in the business environment both globally and in Japan.” More: Moderna, facing uncertain business environment, scraps plan to establish mRNA plant
read moreFollowing a tumultuous week for Sarepta Therapeutics, the biotech has confirmed that a third patient has died after receiving one of the company’s gene therapies. On an investor call Friday, analysts grilled the company over its apparent lack of transparency
read moreMembers of the FDA’s Oncologic Drugs Advisory Committee voiced concerns with ocular toxicity side effects, proposed dosing and a lack of diversity in GSK’s trial program. More: FDA advisors spurn GSK's Blenrep comeback dreams on safety, trial concerns Source: fierce
read moreAfter a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of senators has released a report suggesting the platforms may allow pharmas to inappropriately influence doctors’ prescribing habits. More: 'Abuse of power': Senators call
read more
First patient dosed in BUOY-1 study targeting MDD with or without anxious distress More: Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals